Matthew Rosencranz

Matthew Rosencranz is an associate in Goodwin’s Business Law department and a member of its nationally recognized Technology and Life Sciences groups. Matthew advises companies on a wide array of corporate matters, including seed, venture and growth equity financings, public securities offerings, mergers and acquisitions, and other strategic transactions. He also represents a number of publicly traded companies in ongoing SEC compliance matters.

Matthew also represents growth equity and venture capital investors, advising them on structuring and executing their investment transactions. He joined Goodwin in 2019.

Matthew’s recent representations, among others, include advising:

Capital Markets and Mergers & Acquisitions:

• Klaviyo in its $659 million initial public offering
• The underwriters in Oscar Health’s $1.4 billion initial public offering
• The underwriters in Royalty Pharma's $728 million follow-on public offering
• The purchasers in Arch Resources’ upsized $155.25 million convertible senior notes offering
• Moderna in its investment and strategic collaboration with Generation Bio
• Mobeewave in its $115 million stock sale to Apple
• Allego in its acquisition of Refract
• Stadion Money Management in its asset sale to North Square Investments
• Brightcove in its acquisition of HapYak
• Brightcove in its acquisition of Wicket Labs
• Virex Health in its sale to Sorrento Therapeutics
• Circle Internet Financial in its acquisition of Elements Pay
• Klaviyo in its acquisition of Napkin.io
• COMPASS Pathways in its $147 million initial public offering
• Dynatrace in its public secondary follow-on offerings

Private Financings:

• Klaviyo in its $320 million common stock financing
• Klaviyo in its strategic partnership with Shopify
• Allego in its venture capital financings
• MANA Therapeutics in its $42 million Series A financing
• MBX Biosciences in its $35 million Series A financing
• Kymera in its $102 million Series C financing
• Obsidian Therapeutics in its $115 million Series B financing
• Obsidian Therapeutics in its $160 million Series C financing
• SmarterX in its venture capital financings
• Sensory Cloud in its venture capital financings
• THINKMD in its Series Seed financing
• TVision in its Senior Series C financing
• Investors in DSP Concepts’ Series C financing
• Numerous other private companies, growth equity firms and venture capital firms, including Curie Bio, DST Global, Mendon Venture Partners, Milky Way Investments, Will Ventures and others in connection with their portfolio companies, and equity, SAFE and debt financings

While in law school, Matthew served as a judicial intern at the U.S. District Court for the District of Massachusetts and at the Massachusetts Supreme Judicial Court. He also served as an editor of the Suffolk University Law Review.